(+/-)-2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylic acid ethyl ester | 557101-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (+/-)-2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylic acid ethyl ester
• 英文别名: 2-amino-9,10-dimethoxy-1,6,7,11lb-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylic acid ethyl ester；2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylic acid ethyl ester；ethyl 2-amino-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine-3-carboxylate
• CAS: 557101-39-0
• 化学式: C₁₈H₂₄N₂O₄
• 分子量: 332.4
• InChiKey: KJLKBWRENGBSKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (+/-)-2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylic acid ethyl ester 在 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 1.17h， 生成 ethyl (2S,3S,11bS)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine-3-carboxylate
  参考文献：
  名称：

  Pyrido [2,1-a] isoquinoline derivatives

  摘要：

  本发明涉及式(I)化合物，其中R1如描述中所定义，并且其药学上可接受的盐。该化合物可用于治疗和/或预防与DPP-IV相关的疾病，如糖尿病，特别是非胰岛素依赖性糖尿病和糖耐量受损。

  公开号：

  US20040259902A1
• 作为产物：
  描述：

  (+/-)-1-(3-ethoxycarbonyl-2-oxo-propyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolinium chloride 在 ammonium acetate 、 sodium acetate 作用下， 以 甲醇 、 水 为溶剂， 生成 (+/-)-2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  c

  摘要：

  DOI：

  c

文献信息

• PROCESS FOR THE PREPARATION OF PYRIDO [ 2-1-A] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE
  申请人：Abrecht Stefan

  公开号：US20080076925A1

  公开（公告）日：2008-03-27

  The invention relates to a process for the preparation of pyrido[2,1- a ] isoquinoline derivatives of the formula wherein R 2 , R 3 and R 4 are as defined in the specification, comprising the steps of a) catalytic asymmetric hydrogenation of an enamine of the formula wherein R 1 is lower alkyl, in the presence of a transition metal catalyst containing a chiral diphosphane ligand, b) introduction of an amino protecting group Prot and c) amidation of the ester to form an amide of formula wherein R 2 , R 3 , R 4 and Prot are as defined in the specification.

  本发明涉及一种制备式为的吡啶并[2,1-a]异喹啉衍生物的方法，其中R2、R3和R4如规范中所定义，包括以下步骤：a）在手性二膦配体存在下，对式为的烯胺进行催化不对称氢化，其中R1为低碳基；b）引入氨基保护基Prot；c）酰胺化酯，形成式为的酰胺，其中R2、R3、R4和Prot如规范中所定义。
• PROCESS FOR THE PREPARATION OF PYRIDO [2,1-a] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE
  申请人：Abrecht Stefan

  公开号：US20080071087A1

  公开（公告）日：2008-03-20

  This invention relates to a process for the preparation of pyrido[2,1-a]isoquinoline derivatives of the formula wherein R 1 , R 2 , R 3 and R 4 are defined in the specification, comprising the optical resolution of an enamine of the formula wherein R 1 is lower alkyl, in the presence of an optical active resolving agent to form an (S)-enamine salt of the formula wherein RCO 2 − is the conjugate base of the resolving agent.

  本发明涉及一种制备式为pyrido[2,1-a]异喹啉衍生物的方法，其中R1、R2、R3和R4在规范中有定义，包括在具有手性分离剂的存在下，光学分辨式为R1为低级烷基的恩酰胺，形成式为RCO2-的手性(S)-恩酰胺盐。
• Pyrido[2,1-a]isoquinoline derivatives
  申请人：Gobbi Luca Claudio

  公开号：US06897222B2

  公开（公告）日：2005-05-24

  The present invention provides compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供式（I）的化合物：其中R1、R2、R3、R4、R5和R6如规范中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与DPP-IV相关的疾病，例如糖尿病，特别是非胰岛素依赖性糖尿病和糖耐量受损。
• Pyrido[2,1-A]Isoquinoline derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US06727261B2

  公开（公告）日：2004-04-27

  The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了式（I）的化合物，其中R1、R2、R3、R4、R5和R6如规范中所定义，并且它们的药物可接受的盐。这些化合物可用于治疗和/或预防与DPP-IV相关的疾病，例如糖尿病，特别是非胰岛素依赖性糖尿病和糖耐量受损。
• PROCESS FOR THE PREPARATION OF PYRIDO [2,1-A] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE
  申请人：Abrecht Stefan

  公开号：US20130018191A1

  公开（公告）日：2013-01-17

  This invention relates to a process for the preparation of pyrido[2,1-a] isoquinoline derivatives of the formula wherein R 1 , R 2 , R 3 and R 4 are defined in the specification, comprising the optical resolution of an enamine of the formula wherein R 1 is lower alkyl, in the presence of an optical active resolving agent to form an (S)-enamine salt of the formula wherein RCO 2 − is the conjugate base of the resolving agent.

  本发明涉及一种制备式为pyrido [2,1-a] isoquinoline衍生物的过程，其中R1、R2、R3和R4在说明书中定义，包括在光学活性分离剂的存在下对式为的烯胺进行光学分辨，以形成式为的（S）-烯胺盐，其中RCO2-是分离剂的共轭碱基。